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Abstract
Background: Pre-elafin/trappin-2 is a human innate defense molecule initially described as a potent inhibitor of
neutrophil elastase. The full-length protein as well as the N-terminal “cementoin” and C-terminal “elafin” domains
were also shown to possess broad antimicrobial activity, namely against the opportunistic pathogen P. aeruginosa.
The mode of action of these peptides has, however, yet to be fully elucidated. Both domains of pre-elafin/trappin-
2 are polycationic, but only the structure of the elafin domain is currently known. The aim of the present study
was to determine the secondary structures of the cementoin domain and to characterize the antibacterial
properties of these peptides against P. aeruginosa.
Results: We show here that the cementoin domain adopts an a-helical conformation both by circular dichroism
and nuclear magnetic resonance analyses in the presence of membrane mimetics, a characteristic shared with a
large number of linear polycationic antimicrobial peptides. However, pre-elafin/trappin-2 and its domains display
only weak lytic properties, as assessed by scanning electron micrography, outer and inner membrane
depolarization studies with P. aeruginosa and leakage of liposome-entrapped calcein. Confocal microscopy of
fluorescein-labeled pre-elafin/trappin-2 suggests that this protein possesses the ability to translocate across
membranes. This correlates with the finding that pre-elafin/trappin-2 and elafin bind to DNA in vitro and attenuate
the expression of some P. aeruginosa virulence factors, namely the biofilm formation and the secretion of
pyoverdine.
Conclusions: The N-terminal cementoin domain adopts a-helical secondary structures in a membrane mimetic
environment, which is common in antimicrobial peptides. However, unlike numerous linear polycationic
antimicrobial peptides, membrane disruption does not appear to be the main function of either cementoin, elafin
or full-length pre-elafin/trappin-2 against P. aeruginosa. Our results rather suggest that pre-elafin/trappin-2 and
elafin, but not cementoin, possess the ability to modulate the expression of some P.aeruginosa virulence factors,
possibly through acting on intracellular targets.
Background
Pseudomonas aeruginosa is a Gram-negative bacterium
that rarely causes serious infections in healthy indivi-
duals. It is, however, the prevalent opportunist pathogen
encountered in nosocomial infections and the major
etiologic agent responsible for the morbidity, clinical
deterioration and early mortality associated with patients
suffering from cystic fibrosis (CF) [1-5]. A plethora of
virulence factors expressed by P. aeruginosa is associated
with acute and chronic infections [6]. Perhaps the most
dramatic change that characterizes P. aeruginosa chronic
infections is the transformation from a non-mucoid to a
mucoid phenotype [7]. This is associated with an over-
production of alginate, which favors biofilm formation
and an increased antibiotic resistance [8]. Chronic pseu-
domonal infections are thought to be virtually impossi-
ble to eradicate and the current strategy in the
management of CF patients, which become infected in
their early childhood, is to prevent or retard progression
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with conventional antibiotic therapy as soon as they
appear [9,10].
In this era of increased antibiotic resistance, the devel-
opment of novel antimicrobial agents is urgently needed.
In the past decade, gene-encoded short positively
charged peptides, collectively known as antimicrobial
peptides (AMP), have attracted much attention because
of their broad antimicrobial activities and their potential
use as therapeutics [11-18]. AMP are characterized by
their short length (12-50 aa), polycationic (at least +2
net charge as Lys or Arg) and, usually, amphipathic
characters. Among the nearly thousand identified pep-
tides from various organisms, four classes can be distin-
guished based on their structures; (i) amphipathic
a-helical, (ii) b-sheet structures; (iii) extended struc-
tures, and (iv) hairpin loop stabilized by a single disul-
fide bridge. A common feature ascribed to AMP is their
ability to interact with the negatively charged bacterial
membranes and polyanionic cell surface (lipopolysac-
charide (LPS) of Gram-negative and lipoteichoic acid of
Gram-positive bacteria). At their lethal concentrations
in vitro, they generally disrupt membrane integrity and
cause bacterial lysis. Some AMP, however, do not cause
membrane disruption, but act on intracellular targets
such as nucleic acids [19].
We are studying the human multifunctional innate
defense molecule known as pre-elafin/trappin-2. This
protein is composed of two domains, an N-terminal
moiety of 38 aa known as cementoin based on its ability
to be cross-linked to extracellular matrix proteins
through the action of a transglutaminase and a C-term-
inal part of 57 aa, or elafin domain, that displays
sequence similarity with whey acidic protein (WAP)
[20]. This latter domain is a potent and specific inhibi-
tor of neutrophil elastase (NE) and myeloblastin, as well
as pancreatic elastase [21,22]. Its structure was deter-
mined both by X-ray crystallography in complex with
pancreatic elastase and free in solution by nuclear mag-
netic resonance (NMR) spectroscopy [23,24]. The salient
structural feature of elafin is a b-sheet stabilized by
three disulfide bridges along with an inhibitory loop
connected to the central b- s h e e tb yaf o u r t hd i s u l f i d e
bridge. There is no structural information regarding the
cementoin domain or the full-length pre-elafin
molecule.
Apart from the well-known inhibitory and anti-inflam-
matory properties of pre-elafin/trappin-2, previous stu-
dies also established that the full-length molecule and
each of its domains possess broad antimicrobial activity,
namely against the bacteria P. aeruginosa and S. aureus,
and the yeast C. albicans [25-28]. Furthermore, adeno-
viral overexpression of pre-elafin/trappin-2 in a mouse
model of acute P.aeruginosa infection was shown to
reduce the bacterial load and to facilitate clearance of
the microorganism [29]. Although it has been documen-
ted that the full-length molecule is more active than its
constituent domains in vitro [25,27,28], the exact
mechanism of action of each of these peptides against
microbial infections is largely unknown. We recently
reported that the variable sensitivity of P. aeruginosa
strains to pre-elafin/trappin-2 could be partly explained
by the specific inhibition of a peptidase secreted by
some, but not all, strains by the elafin domain [27].
However, both domains also display antimicrobial activ-
ity independent from the peptidase inhibitory function
of elafin suggesting that the antimicrobial properties of
these peptides are the sum of several unique attributes
[27,28].
I nt h ep r e s e n ts t u d yw eh a v ed e t e r m i n e dt h es e c o n d -
ary structures of the cementoin peptide in the presence
or absence of membrane mimetics. This peptide is
essentially unstructured in aqueous solution but, like a
large class of AMPs, adopts an a-helical conformation
in the hydrophobic membrane environment. However,
when compared with magainin-2, a typical a-helical
AMP with potent lytic activity [30], the lytic properties
of cementoin, elafin or pre-elafin/trappin-2 toward P.
aeruginosa and artificial membranes are very weak. We
have also tested the ability of pre-elafin/trappin-2 and
its domains to interfere with the expression of known P.
aeruginosa virulence factors and compared this activity
to that of azithromycin, an antibiotic that perturbs cell
to cell communication in P. aeruginosa and significantly
retards biofilm formation [31,32]. Pre-elafin/trappin-2
and elafin, but not cementoin, were found to reduce
biofilm development and the secretion of pyoverdine
and this correlated with the ability of these peptides to
bind DNA in vitro and to accumulate within the bacter-
ial cytosol. Rather than causing extensive cell lysis, our
data thus suggest that pre-elafin/trappin-2 and elafin
attenuate the expression of some P. aeruginosa virulence
factors, possibly through acting on an intracellular
target.
Results
The cementoin domain of pre-elafin/trappin-2 adopts an
a-helical conformation in the presence of membrane
mimetics
Different experiments were performed to characterize
the structure of cementoin and its interaction with
membranes. First, we recorded circular dichroism (CD)
spectra in the presence or absence of trifluoroethanol
(TFE), which mimics a membrane environment [33]
(Fig. 1A). In an aqueous solution, the CD spectrum is
typical of an unstructured protein with a prominent
negative peak at 199 nm. When TFE was added, the
intensity of this peak decreased concomitantly with the
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Figure 1 Biophysical characterization of cementoin. A) CD spectra of cementoin with varying concentrations of TFE (up to 75%). The vertical
lines indicate 208 and 222 nm, i.e. characteristic wavelengths for assessing the presence of a-helices. B) 2 D
15N-HSQC spectrum of cementoin
in the presence of 50% TFE. Backbone assignments are shown. Side-chain Asn, Gln and Arg doublets are depicted with a line between the two
resonances while unassigned additional peaks (potentially arising from slow exchange, see text) are labeled by an asterisk (*). C) SSP analysis of
backbone Ca and Cb chemical shifts. Secondary structure predictions depend on the result where positive values infer a-helices and negative
values, b-sheets. D) Secondary structure predictions from AGADIR with a-helices shown as black boxes.
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whose intensity increased with the concentration of
TFE. This is characteristic of an a-helical structure and
the a-helical content of cementoin was estimated to be
48% in 50% TFE and up to 58% in 75% TFE. The
observed isodichroic point at 203 nm indicates that the
transition between the unstructured to the a-helical
conformation is a two-state transition. Hence, a hydro-
phobic environment either induces or stabilizes a-
helices in cementoin. This is in agreement with the
AGADIR algorithm (Fig. 1D), which predicts the forma-
tion of two a-helices in cementoin: helix 1 with residues
10- 16 and helix 2 with residues 24-31, for a predicted
total a-helical content of 39%.
Using NMR, such a formation of structure upon addi-
tion of TFE was also apparent from the more dispersed
1H chemical shifts observed in the presence of 50% TFE
(data not shown). These conditions were thus chosen to
determine the secondary structures of cementoin. A ser-
ies of triple-resonance spectra were recorded in order to
assign backbone chemical shifts (Fig. 1B). From the
assigned backbone chemical shifts, it was possible to
predict secondary structures using the SSP approach
(see Methods). This yielded two predicted helices in
cementoin (Fig. 1C), similar to that predicted by AGA-
DIR (Fig. 1D). Atomic resolution on spin relaxation data
(R1,R 2, NOE; see additional file 1: Fig. S1 A) confirmed
most of AGADIR predictions. Indeed, residues for
which high flexibility is inferred (from reduced spectral
density mapping of spin relaxation data, see Fig. S1 B &
C) are those located right before helix 1 as proposed by
AGADIR, and directly after helix 2. Additionally, R2
data with higher values within proposed a - helices, but
also in the middle of the peptide would tend to indicate
that this whole section of the peptide is in slow
exchange. Hence, both proposed a-helices could be
nucleating points where a - helical structures would
start appearing, enabling the transient existence of a
long a-helix spanning residues 10-31. Of course, this
structure would be transient as the NOE values are
quite low (~0.5) for this whole stretch.
We previously showed that pre-elafin/trappin-2, elafin
and particularly the cementoin domain interact strongly
with negatively charged liposomes composed of phos-
phatidyl glycerol (PG) [27]. We used NMR with bicelles
composed of a mixture of dihexanoyl phosphatidylcho-
line (DHPC), dimyristoyl phosphatidylcholine (DMPC)
and dimyristoyl phosphatidylglycerol (DMPG) to a final
ratio of 8:3:1 to characterize this interaction, by measur-
ing the translational diffusion coefficients for cementoin
in the absence and presence of bicelles (Table 1 and
additional file 1: Fig. S2). In the presence of bicelles,
cementoin diffused with a rate much slower (1.24 × 10
-6
cm
2.s
-1)t h a ni na na q u e o u se n v i r o n m e n t( 4 . 2 8×1 0
-6
cm
2.s
-1). It is important to note here that this effect of
bicelles on slowing the diffusion of cementoin is not
caused by an increase in solvent viscosity, since water
was found to diffuse at approximately the same rate in
both conditions (Table 1). This slower rate is close to
that measured for the bicelles alone (0.79 × 10
-6 cm
2.s
-1;
Table 1 and Fig. S2). This finding convincingly demon-
strates that an interaction exists between cementoin and
bicelles. From these data, the fraction of cementoin
bound to bicelles was estimated to be 87% (see Meth-
ods), implying that ~13% cementoin would be free in
solution. These numbers could also mean that the inter-
action is weak and transient and that, at a given
moment, 87% of cementoin are bound. The exact
mechanism of interaction with membranes would
depend on whether the a-helical structures in cemen-
toin are limited to those two a -helices proposed by
AGADIR and chemical shifts or to a longer a -helix
spanning residues 10-31 that would allow penetration of
cementoin through the entire membrane width. Our dif-
fusion data cannot discriminate between these different
possibilities.
Binding of pre-elafin/trappin-2 peptides to P. aeruginosa
or artificial membranes does not cause extensive
membrane disruption
Positively charged a-helical peptides like cementoin, are
characteristic of many AMPs. These were previously
shown to either disrupt membranes and cause bacterial
lysis or to translocate into the bacterial cytoplasm with-
out causing cell lysis [19]. To obtain information about
the mode of action of recombinant cementoin compared
Table 1 Diffusion behavior of cementoin in H2O and bicelles.
Experimental condition H2O DHPC DMPC
1 cementoin (amide)
2 cementoin (aliphatic)
3
cementoin 25.22 - - 4.27 4.28
DHPC: DMPC: DMPG (8:3:1) 21.07 0.68 0.38 - -
DHPC: DMPC: DMPG (8:3:1) + cementoin 21.08 0.97 0.61 1.25 1.23
Diffusion coefficients* are displayed for bicelles (DHPC + DMPC), H2O and cementoin in either of three experimental conditions in units of 10
-6 cm
2/s.
* Calculated from AG =A 0 exp[-(gδG)
2 (Δ - δ/3) Ds ]
1 DMPG resonance was not observed and assumed to be overlapped with DMPC.
2 From an isolated resonance at 7.4 ppm.
3 Values are the average of three different resonances at 2.0, 2.1 and 3.0 ppm.
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nosa, we first examined the effect of these peptides on
bacteria by scanning electron micrography (SEM). As
shown in Fig. 2, both elafin and cementoin significantly
modified the appearance of P. aeruginosa cell surface
with clear evidence of wrinkling, blister formation and
t h ep r e s e n c eo fp o r e - l i k es t ructures (white arrows in
Fig. 2). At the same concentration, pre-elafin/trappin-2
appeared to affect less severely the bacterial morphology
and cells harboring pore-like structures were much less
abundant. The presence of pores suggests that mem-
brane integrity is compromised by addition of these
peptides. However, ghost cells were rarely observed. In
sharp contrast, when P. aeruginosa were exposed to
magainin 2, a lytic AMP, much fewer cells could be
visualized by SEM and ghost cells were numerous indi-
cating cell lysis (white arrowheads in Fig. 2).
To further document that membrane disruption may
not be the primary role of cementoin, elafin and pre-
elafin/trappin-2, the ability of these peptides to cause
membrane depolarization using the fluorescent probes,
1-N-phenylnaphthylamine (NPN) and 3,3’-d i p r o -
pylthiacarbocyanine (DiSC3) was tested. NPN is a neu-
tral hydrophobic probe that is excluded by an intact
outer membrane, but is taken up into the membrane
interior of an outer membrane that is disrupted by
antimicrobial peptide action [34]. NPN fluoresces
weakly in free solution but strongly when it crosses the
outer membrane barrier into the cell. As shown in Fig.
3( top panel), upon addition of 10 μMm a g a i n i n2a
sharp increase in fluorescence was observed. The addi-
tion of 20 μM pre-elafin/trappin-2 led to a much
weaker fluorescence signal, and 100 μM cementoin or
20 μM elafin had no effects on membrane depolariza-
tion. No variation of fluorescence was seen upon addi-
tion of NPN to bacterial cells when no peptide was
added. To evaluate the effects of the recombinant pep-
tides on P. aeruginosa cytoplasmic membrane, the
fluorescent probe DiSC3 was used. DiSC3 distributes
between the cells and the medium. This cationic dye
concentrates in the cytoplasmic membrane under the
influence of the membrane potential resulting in a self-
quenching of fluorescence. If the membrane is depolar-
ized, the probe will be released into the medium, caus-
ing a measurable increase in fluorescence [35]. The
assays were again compared with magainin 2, which
can permeabilize the bacterial membranes. In contrast
to a strong release of fluorescence upon addition of
magainin 2, pre-elafin/trappin-2 and derived peptides
weakly, if at all, induced fluorescence emission (Fig. 3;
bottom panel). Our results suggest that pre-elafin/trap-
pin-2 and derived peptides, in contrast to magainin 2,
acted on the outer and inner membranes without caus-
ing extensive membrane depolarization.
Figure 2 Scanning electron micrographs of P. aeruginosa
incubated with cementoin, elafin, pre-elafin/trappin-2 or
magainin 2. P. aeruginosa (~1 × 10
7 in 500 μL) were incubated 2 h
with the indicated peptides before being processed for scanning
electron microscopy as described in Methods. CNT; control
performed in the absence of peptides, PE; pre-elafin/trappin-2, Cem;
cementoin, Ela; elafin, Mag; magainin 2. White arrows point to pore-
like structures and white arrowheads to ghost bacterial cells.
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tides by measuring the release of calcein entrapped
within PG-composed liposomes. A 15-min exposure of
liposome-entrapped calcein with magainin 2 led to a
32% release of calcein relative to that measured for lipo-
somes permeabilized with 1% Triton X-100. In contrast,
no more than 5% of calcein was released by either
cementoin, elafin or pre-elafin/trappin-2. We thus con-
clude that these peptides have very weak lytic activities.
This explains our finding that no measurable MIC
(minimal inhibitory concentration) could be measured
even if high concentrations of peptides were tested (up
to 128 μg/mL for pre-elafin/trappin-2 and elafin and up
to 256 μg/mL for cementoin).
Fluorescein-labeled pre-elafin/trappin-2 incubated with P.
aeruginosa accumulates within the cytosol and both
elafin and pre-elafin/trappin-2 bind DNA in vitro
Weak membrane depolarization and leakage of lipo-
some-entrapped calcein, while indicating little mem-
brane disruption, does not exclude that transient pores
may form upon incubation of P. aeruginosa with pre-
elafin/trappin-2 and derived peptides, as suggested by
SEM examination. Formation of transient pores could
lead to the translocation of the peptides across mem-
branes. We previously reported that fluorescein-labeled
pre-elafin/trappin-2 heavily decorated P. aeruginosa cells
as assessed by fluorescence microscopy [27]. Here we
used confocal microscopy to examine the fate of fluores-
cein-labeled pre-elafin/trappin-2 upon a 1 h incubation
with P. aeruginosa. As shown in Fig. 4, the whole bac-
terial cell was fluorescent in all consecutive 0.2 μms e c -
tions. This is taken as evidence that pre-elafin/trappin-2
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Figure 3 Depolarization of P. aeruginosa membranes upon
incubation with magainin 2, pre-elafin/trappin-2 or derived
peptides. Fluorescence emission (arbitrary units) of the probe NPN
inserted into the outer membrane (top panel)o rt h ep r o b eD i S C 3
inserted into the inner membrane (bottom panel)o fP. aeruginosa
upon addition of the indicated peptides. The controls were performed
in phosphate buffer alone. Pre-elafin/trappin-2 and elafin were used at
20 μM, cementoin at 100 μM and magainin 2 at 10 μM. The arrow
indicates the time-point for the addition of the various peptides.
Figure 4 Confocal microscopy of P. aeruginosa incubated with fluorescein-labeled pre-elafin/trappin-2. Mid-logarithmic phase cultures of
P. aeruginosa were incubated for 1 h at 37°C with fluorescein-labeled pre-elafin/trappin-2 and observed by confocal microscopy at 400 ×
magnification. From left to right, consecutive 0.2 μm sections of a fluorescent bacterial cell.
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the bacterial cytosol.
Given the polycationic character of pre-elafin/trap-
pin-2 and derived peptides and the apparent ability of
pre-elafin/trappin-2 to traverse lipid bilayers, we con-
sidered the possibility that they could interact with
nucleic acids. To test this hypothesis, we evaluated
whether any of the pre-elafin/trappin-2 and derived
peptides could induce an electrophoretic mobility shift
(EMSA) of DNA. As shown in Fig. 5, the EMSA assay
revealed that pre-elafin/trappin-2 binds to DNA in
vitro at a peptide:DNA ratio of 5:1 and greater. Similar
results were also obtained with the elafin domain. In
contrast, no DNA shift was observed for the cementoin
peptide up to a 100:1 ratio. Hence, despite the fact that
the cementoin peptide has a greater positive charge
(+4) than elafin (+3), the structure of the elafin domain
appears necessary and sufficient for binding to DNA
in vitro.
Pre-elafin/trappin-2 and elafin attenuate the expression
of known P. aeruginosa virulence factors
To test whether the binding and/or translocation of the
pre-elafin/trappin-2 and derived peptides could modify
the behavior of P. aeruginosa, we assayed the expression
of known virulence factors in the absence or presence of
the various peptides and this was compared to that
observed in the presence of azithromycin. At sublethal
concentrations, azithromycin is known to interfere with
the quorum sensing of P. aeruginosa and this was
reported to reduce the expression of numerous genes
encoding virulence factors as well as to retard formation
of a biofilm [31,32,36]. We specifically assayed for the
secretion of the siderophore pyoverdine, the peptidase
lasB, the production of alginate and the development of
a biofilm. Apart from the biofim development, which
was estimated after 26 h of growth in the presence or
absence of peptides, all assays were carried out on 24 h
cultures of P. aeruginosa.A ss h o w ni nT a b l e2 ,p r e - e l a -
fin/trappin-2 was the most effective peptide in all assays,
and at 8 μM it reduced the secretion of pyoverdine and
the formation of a biofilm by ~40%. At this concentra-
tion, it also reduced by approximately 25% the secretion
of lasB and alginate although not in strictly dose-depen-
dent manner. Interestingly, the effect of pre-elafin/trap-
p i n - 2p a r a l l e l e dt h a to fa z i t h r o m y c i nu s e da tt h es a m e
concentrations. Compared to pre-elafin/trappin-2 and
azithromycin, the elafin peptide was only modestly less
efficient with an observed ~30% reduction on the secre-
tion of pyoverdine and biofilm formation. The cemen-
toin peptide alone barely (4 μM) or modestly (8 μM)
affected the expression of these virulence factors. Hence,
both pre-elafin/trappin-2 and elafin appear to attenuate
the expression of some P. aeruginosa virulence factors
and this correlates with their ability to bind DNA
in vitro.
2
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Figure 5 Electrophoretic mobility shift assay of plasmid DNA incubated in the absence or presence of pre-elafin/trappin-2, elafin and
cementoin. Plasmid pRS426 (100 ng) was incubated with the indicated ratios of peptide/DNA (w/w) for 1 h and then analyzed by agarose gel
electrophoresis followed by staining with ethidium bromide. Above are representative gels from an experiment performed in triplicata. M; 1 kb
DNA ladder from Invitrogen.
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The aim of the present study was to determine the sec-
ondary structures of the N-terminal moiety of pre-ela-
fin/trappin-2 (cementoin) and to investigate the mode of
action of this peptide compared to elafin and pre-elafin/
trappin-2 against P. aeruginosa. We have shown here by
CD and NMR studies that the cementoin peptide is
essentially unstructured in aqueous solution but adopts
an a-helical conformation in the presence of a mem-
brane mimetic (TFE). This characteristic is shared with
the most important class of AMP, the linear polycatio-
nic peptides [33], which include the human LL-37 pep-
tide [37]. Whilst TFE is known to induce a-helical
structures by favoring intra hydrogen bonding, it has
been demonstrated for a large number of AMP that this
propensity to adopt an a-helical conformation in TFE is
also observed in the presence of artificial membranes
that more closely mimic the physiological environment
[33]. Hence, the secondary structures determined for
cementoin in the presence of TFE are likely to be phy-
siologically relevant. Previous studies showed that
cementoin binds to the lipid core of lipopolysachharide
(LPS) [27,38] as well as to artificial membranes, particu-
larly the negatively charged membranes enriched in PG
[27]. We confirmed here these finding by demonstrating
that the translational diffusion of cementoin in the pre-
sence of DMPG-containing bicelles is considerably
slower than that of free cementoin. Furthermore, we
estimated that under the conditions used (peptide:lipid
millimolar ratio of 1:200), approximately 87% of the
cementoin peptide was bound to bicelles.
As revealed by SEM, binding of cementoin to P. aeru-
ginosa elicited obvious morphological changes such as
wrinkling and blister formation on the cell surface and
the presence of pore-like structures. This is reminiscent
to that described earlier for the binding of pre-elafin/
trappin-2 to P. aeruginosa by Baranger et al. [28]. How-
ever, in our hands the morphological changes induced
by pre-elafin/trappin-2 were not as severe as those
reported earlier or to that observed in the present study
with cementoin and elafin alone. The reason for this
apparent discrepancy is not clear but could be due to a
different peptide to bacteria ratio and/or to the actual
fraction of mature elafin present in the two preparations
of pre-elafin/trappin-2. It is generally assumed that the
presence of pore-like structures is indicative of cell lysis.
However, several lines of evidence suggest that the
membrane disruption properties of cementoin, elafin
and pre-elafin/trappin-2 are considerably weaker com-
pared to that of the amphibian lytic AMP magainin 2.
First, unlike that observed with pre-elafin and derived
peptides, numerous ghost cells were visualized by SEM
upon incubation of P. aeruginosa with magainin 2. Sec-
ond, compared to this AMP, outer and inner membrane
depolarization by pre-elafin/trappin-2, elafin and cemen-
toin, as measured with the probes NPN and DiSC3,
were significantly weaker. Third, the release of lipo-
some-entrapped calcein by magainin 2 was six-fold
greater than that measured with any of the pre-elafin/
trappin-2 derived peptides. Finally, no MIC values could
be determined for cementoin, elafin or pre-elafin/trap-
p i n - 2c o m p a r e dt oaM I Co f8μg/mL for magainin 2
against P. aeruginosa ATCC 27853 strain [39]. We
therefore tentatively conclude that membrane disruption
per se may not be the main function of these peptides
in vivo.
Historically, the lytic properties of a peptide were
important criteria to classify it as an AMP. It is however
becoming increasingly documented that several AMP
possess other functions such as modulating the host
response, through interacting with innate defense mole-
cules, or modifying the microbial behavior by acting on
intracellular targets [19,40,41]. In line with this notion,
pre-elafin/trappin-2 was recently proposed to opsonize
P. aeruginosa to facilitate its clearance by macrophage
[42]. In the present work, we provided evidence that
pre-elafin/trappin-2 may also traverse membranes, pre-
sumably to act on intracellular targets. A potential target
could be DNA as both elafin and pre-elafin/trappin-2
were shown to bind DNA in vitro and this correlated
with their ability to attenuate the expression of some P.
aeruginosa virulence factors (see below). Buforin II is
perhaps the best-documented AMP that acts on an
intracellular target, the nucleic acids [43,44]. Investiga-
tion of the membrane translocation mechanism of
buforin II led to the proposal that this peptide induces
the formation of a toroidal pore similar to that
described for magainin 2 [45]. However, unlike magainin
2, the short lifetime of the pore enables translocation of
the peptide without causing membrane permeabilization
Table 2 Attenuation of P. aeruginosa virulence factors by
pre-elafin/trappin-2, elafin and cementoin
Peptide [μM] %
1
Pyoverdine
% Las
B
%
Alginate
%
Biofilm
Pre-elafin/
trappin-2
4 7 1±2 8 3±2 7 6±2 7 0±2
8 5 9±2 7 5±2 7 2±2 5 7±4
Elafin 4 82 ± 2 87 ± 4 79 ± 3 86 ± 2
8 6 9±1 7 3±5 7 7±2 6 9±2
Cementoin 4 96 ± 2 96 ± 4 95 ± 1 94 ± 2
8 9 1±1 8 8±4 8 7±2 8 7±2
Azithromycin 4 69 ± 2 85 ± 4 80 ± 3 62 ± 4
8 5 5±2 7 6±2 7 5±3 4 4±5
1The results are expressed as a percentage ± SD relative to P. aeruginosa
cultures grown in the absence of peptides, which were set at 100%. For the
assays of pyoverdine and lasB the values represent the mean of 3
experiments performed in duplicata. For the assays of alginate and biofilm
formation the values represent the mean of 3 experiments.
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brane depolarization and calcein release observed with
pre-elafin/trappin-2 and elafin suggest that these pep-
tides might be similarly translocated across lipid bilayers
without causing extensive cell lysis. However, we cannot
exclude the possibility that like Gramicidin A the size of
the pores, rather than their lifetime, explains the weak
membrane depolarization and calcein release observed
[46]. Future investigations using solid-state NMR to
further characterize the interaction between pre-elafin/
trappin-2 peptides and model membranes are needed to
confirm their translocation properties and the exact
mechanism involved.
Azithromycin is not considered an effective antibiotic
against P. aeruginosa due to its high MIC value (> 64
μg/mL; [31,47]). Yet, at sublethal concentrations for P.
aeruginosa, azithromycin was found to retard biofilm
formation [32] and to reduce the production of alginate,
pyocyanin and the secretion of elastase (lasB) [31,36].
We confirmed here these previous data and showed that
it also reduces secretion of the siderophore pyoverdine.
Both pre-elafin/trappin-2 and elafin were found to simi-
larly affect the expression of P. aeruginosa virulence fac-
tors, namely the biofilm formation and the secretion of
pyoverdine. Because these peptides were previously
found to reduce the plating efficiency (cfu) of P. aerugi-
nosa following a 3 h incubation with the peptides in
phosphate buffer [25,27], it could be argued that the
observed attenuation on the expression of virulence fac-
tors is indirect. However, we believe this is unlikely for
three reasons. First, all phenotypes were tested following
prolonged incubation periods (ranging from 24 to 26 h)
with the peptides in PSB medium. Under these condi-
tions, the A595 nm of the cultures at the end of the incu-
bation were almost undistinguishable between samples
incubated in the presence or absence of peptides. Sec-
ond, all phenotypes were quantified taking into account
the final A595 nm of the cultures. Finally, whereas the
plating efficiency of P. aeruginosa following a 3 h incu-
bation with the peptides in phosphate buffer varied con-
siderably between different strains (i.e. ATCC 27853 vs
ATCC 33348; [25,27]), this was not found to be the case
for the reduced biofilm formation and secretion of pyo-
verdine between these two strains (data not shown). In
further support to the role of pre-elafin/trappin-2 in the
attenuation of P. aeruginosa virulence factors, it was
recently reported that the A549 cell line expressing pre-
elafin/trappin-2 reduces both the number of bacteria
and the area of growing P. aeruginosa biofilm by
approximately 50% [48]. Although the effect of pre-ela-
fin/trappin-2 and elafin is modest in vitro, this may con-
tribute in vivo, along with the anti-inflammatory
properties of these molecules, to prevent against P. aer-
uginosa infections.
Conclusions
We have demonstrated that the N-terminal moiety of
pre-elafin/trappin-2 (cementoin) adopts an a-helical
conformation in the presence of a membrane mimetic,
which is typical of a large class of AMP. Despite the
morphological changes observed at the surface of P. aer-
uginosa in the presence of cementoin, elafin or pre-ela-
fin/trappin-2, the membrane disruption properties of
these peptides are weak compared to magainin 2. We
provided evidence that pre-elafin/trappin-2 and elafin
may act on an intracellular target, possibly DNA.
Although future studies on the interaction of these pep-
tides with artificial membranes are needed to confirm
and to elucidate the mechanism of membrane transloca-
tion, both pre-elafin/trappin-2 and elafin were shown to
attenuate the expression of some P. aeruginosa virulence
factors, which may contribute to the defense against P.
aeruginosa infection.
Methods
Bacterial, yeast strains and growth conditions
P. aeruginosa strain ATCC #33348 was used in all func-
tional assays with the pre-elafin/trappin- 2 and derived
peptides. Bacteria were grown at 37°C with (250 rpm) or
without agitation in peptone soy broth (PSB). E. coli
strain BL21(DE3) (Novagen, Mississauga, ON, Canada)
was used for the recombinant production of the cemen-
toin peptide. The S. cerevisiae yeast strain YGAU-Ela2
(Mata his3 leu2 ura3 mfa1/mfa2Δ::LEU2 yps1Δ::HIS3
ura3::pGAU-Ela2) was used for the production of pre-
elafin/trappin-2. This strain was constructed by integrat-
ing the plasmid pGAU-Ela2 (see below) digested by NcoI
at the ura3 locus of the YBAD1 strain previously used
for the production of pre-elafin/trappin-2 [49]. Yeast
cells were grown at 30°C in yeast dextrose peptone
(YPD) medium.
Plasmids, oligonucleotides and DNA manipulations
DNA manipulations, bacterial and yeast transformations
were all carried out according to standard procedures
[50,51]. Unless otherwise indicated, all restriction and
DNA-modifying enzymes were purchased from New
England Biolabs Ltd (Pickering, ON, Canada). The bac-
terial expression plasmid pET32-cem has been described
previously for the production of the cementoin domain
[27]. The yeast integration plasmid pGAU-Ela2 was con-
structed by first excising the 2 μ origin of pVT-Ela2
through digestion with BstX1 and SmaI, fill-in with the
Klenow fragment and ligation. Next, the GAL1 promoter
obtained as an EcoRI-BamHI fragment from plasmid
pJK6 [52] was blunt-ended with Klenow and inserted
into the unique PvuII site located upstream of the pre-
elafin fusion protein in pVT-Ela2 [49]. The resulting
integration plasmid was named pGAU-Ela2. All DNA
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sequencing.
Production and purification of recombinant pre-elafin and
cementoin
Growth conditions for the production of bacterially
expressed cementoin peptide were as described previously
[27]. For the production of pre-elafin/trappin-2, the yeast
YGAU-Ela2 strain was first cultured 2 days at 30°C in 3 L
of YPD with daily adjustments of the pH (pH 6.0) and
addition of dextrose (1% w/v). The culture medium was
then replaced by 1 L of synthetic complete -uracil medium
supplemented with galactose 2% and the culture was
resumed for another 2 days at 30°C with twice daily
adjustments of the pH and additions of yeast nitrogen
base (1% w/v) and galactose (1% w/v). Uniformly
15N-
13C-
labeled cementoin samples for NMR spectroscopy were
prepared using
15NH4Cl and [
13C]-glucose (Cambridge
Isotope Laboratories, Andover, MA) as the sole nitrogen
and carbon sources, as previously described [53]. Induc-
tion with 1 mM isopropyl-b-D-thiogalactopyranoside
(IPTG) was performed for 16 h at 37°C.
Purification of recombinant His-tagged pre-elafin/trap-
pin-2 from yeast culture supernatants was essentially as
described [49,54], except the diafiltration proceeded in
two steps. The permeate from a first diafiltration per-
formed with the cleared supernatant over a 30-kDa car-
tridge was followed by concentration on a 3-kDa
cartridge. Purification of the cementoin peptide from
bacterial pellets, either uniformly labeled or not, was as
previously described [27]. Purified peptides were concen-
trated in deionized water using stirred-cells, lyophilized
and stored at -80°C until use. Recombinant human elafin
was purchased from AnaSpec (San Jose, CA, USA).
Structural analysis
CD spectra were recorded using a JASCO J-710 instru-
ment upgraded to J-715 by varying wavelengths between
180 and 250 nm with steps of 0.2 nm. Cementoin was
prepared at a concentration of 1 mg/ml in water supple-
mented with 0% to 75% TFE. The alpha helical content
was obtained from the following formula:
H nm  =− − 100 3000 39000 222 *( )/ ,
where Ha is the percent a-helix and θ,t h em o l a r
ellipticity per residue (deg.cm
2.dmol
-1), was defined as
follows:
 =Δ A.MW/C.n.l,
where MW is the peptide molecular weight (here
3948.54 g/mol), n is the number of residues in the pep-
tide (here 38 residues), C is the peptide concentration
(here 1g/L), and l is the length of the optical course
(here 0.01 cm).
The AGADIR software http://agadir.crg.es/ developed
by the Serrano’s group [55-59] was used to predict the
cementoin secondary structures. The parameters for
ionic strength, temperature and pH were set to 1 M,
278°K and 7.0, respectively.
NMR samples were prepared by dissolving lyophilized
protein in an aqueous solution at pH 6.4 to a final con-
centration of 0.5 mM and with 60 μM 2,2-dimethylsila-
pentane-5-sufonic acid and 10% D2O (for chemical shift
referencing and locking, respectively). The spectra were
recorded at a temperature of 2°C (calibrated with
MeOH) on a 600 MHz Varian INOVA spectrometer
equipped with either a room temperature triple reso-
nance probe or a z-axis pulsed-field gradient triple reso-
nance cold probe. Two-dimensional
15N-HSQC, 3D-
HNCO, 3D-HN(CO)CA, and 3D-CBCA(CO)NH spectra
(Biopack, Varian Inc., Palo Alto, CA) were recorded.
NMR data were processed with NMRPipe/NMRDraw
[60] and analyzed with NMRView [61]. Backbone
assignments proceeded within Smartnotebook v5.1.3
[62]. The chemical shift index was calculated for both
Ca and Cb for secondary structure prediction using the
SSP approach [63].
Experiments for the measurement of diffusion coeffi-
cients by NMR were performed for cementoin in the
absence and presence of bicelles. The procedure used
was as described previously [64]. In summary, the
bicelles used were a mixture of DHPC, DMPC and
DMPG for a final ratio of 8:3:1 (with a (DMPC
+DMPG)/DHPC ratio, i.e. long-chain to short-chain or
q ratio, of 0.5). Experiments were performed with
cementoin at 0.5 mM and were recorded at 37°C. Rates
were extracted using the following equation:
AA G D Gs =− − 0
2 3 exp[ ( ) ( / ) ],   Δ
Where g is
1H gyromagnetic ratio (2.6753 × 10
4 rad.s
-
1.G
-1), δ is the duration of the pulse -field gradient
(PFG, 0.4 s), G is the gradient strength (from 0.5 to 52
G.cm
-1), Δ is the time between PFG trains (0.154 s) and
Ds is the diffusion coefficient (in cm
2.s
-1).
The fraction of cementoin bound to bicelles was esti-
mated with the following equation:
Dp . Dp. D obs free free bound bound =+ ,
where Dobs,D free and Dbound are the diffusion coeffi-
cients for all cementoin states (observed rate: 1.24 cm
2.
s
-1), for free cementoin (4.28 cm
2.s
-1) and for bound
cementoin (by approximation, for bicelles: 0.79 cm
2.s
-1),
respectively, and pfree and pbound are the fractions for
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respectively.
Backbone chemical shifts and spin relaxation data
were deposited in the BMRB under accession number
16845.
Scanning electron micrography
Scanning electron micrography (SEM) of P. aeruginosa
(~1 × 10
7 in 500 μL) incubated for 2 h in the absence
or presence of the indicated peptides (8 μM) was per-
formed on a JEOL JSM-6360LV microscope essentially
as described [28], except samples were placed on Alcar©
films and dehydrated by a series of incubation in alcohol
(50, 70, 95 and 100%).
Outer and inner membrane depolarization of P.
aeruginosa
The outer membrane depolarization activity of the
recombinant peptides was determined by the 1-N-phe-
nylnaphthylamine (NPN) uptake assay of Loh et al. [34]
with intact cells of P. aeruginosa using the Fluorescan
Ascent FL microplate fluorometer. P. aeruginosa was
grown with agitation to an A600 nm = 0.6 and harvested
by centrifugation. The cells were washed in 5 mM
HEPES, pH 7.8 and resuspended to an A600 nm of 0.5 in
the same buffer. The microtiter plate wells were supple-
mented with cells (200 μL) and NPN dissolved in acet-
one was added to a final concentration of 10 μM. Then
peptides were added to the desired concentration and
the intensity of fluorescence was measured at lex =3 5 5
nm and lem = 444 nm.
The cytoplasmic membrane depolarization activity of
the peptides was determined as previously described with
the membrane potential-sensitive dye DiSC3 [35]. Briefly,
P. aeruginosa was grown at 37°C with agitation to an
A600 nm of 0.6 and harvested by centrifugation. The cells
were washed in 5 mM HEPES, pH 7.8 and resuspended
to an A600 nm of 0.05 in the same buffer containing 20
mM glucose and 100 mM KCl. The cells were first trea-
ted with 15 mM EDTA pH 8.0 to permeabilize the outer
membrane and allow the dye to reach the cytoplasmic
membrane. Then, a stock solution of DiSC3 was added to
a final concentration of 0.4 μM, and quenching was
allowed to occur at room temperature. The desired con-
centration of peptides to be tested was added. Membrane
depolarization was monitored with the Fluorescan Ascent
FL microplate fluorometer by observing the change in the
intensity of fluorescence (lex =6 4 6n m ,lem = 678 nm)
after the addition of the peptides.
Preparation of large unilamellar vesicles (liposomes) and
leakage of calcein
Large unilamellar vesicles (liposomes) containing pure
phosphatidylglycerol (PG) were prepared according to
the previously described procedure [27]. Liposome-
entrapped calcein and removal of free calcein by Sepha-
dex G-50 chromatography were carried out essentially
as described [65].
For the calcein release assay, 10 μL of liposome sus-
pension were diluted in 10 mM Tris-HCl pH 7.4, 150
mM NaCl buffer (final vol of 100 μL) and incubated for
15 min at room temperature in the presence or absence
(negative control) of the indicated peptides at 8 μMo r
i nt h ep r e s e n c eo f1 %T r i t o nX - 1 0 0( p o s i t i v ec o n t r o l ) .
The change in the intensity of fluorescence (lex =4 8 5
nm, lem = 527 nm) was monitored with a Fluorescan
Ascent FL microplate fluorometer.
Confocal microscopy
Bacteria were grown at 37°C with agitation in PSB med-
ium to mid-logarithmic phase. Then, the cells were har-
vested by centrifugation, washed three times with 10
mM sodium phosphate buffer, pH 7.4 and resuspended
in the same buffer to an A600 = 0.1. Bacteria were incu-
bated with fluorescein-labeled full-length pre-elafin/trap-
pin-2, prepared as described previously [27], for 1 h at
37°C in the dark. After incubation, cells were washed
three times with phosphate buffer, and bacterial cells
were mounted on a glass slide and microscopic observa-
tions (400 × magnification) of serial 0.2 μms e c t i o n s
were done with a Zeiss LSM 310 confocal microscope.
Images were taken with an Olympus DP20 camera. As a
negative control, free fluorescein incubated with bacteria
and washed under the same conditions gave no fluores-
cent signal (data not shown).
DNA binding assay
EMSA experiments were performed by mixing 100 ng of
plasmid DNA (pRS426) with increasing amounts of
recombinant peptides in 20 μl of binding buffer (5% gly-
cerol, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM
DTT, 20 mM KCl and 5% (w/v) BSA). DNA samples
with or without peptides were co-incubated at room
temperature for 1 h prior to electrophoresis on a 1.0%
agarose gel.
Virulence factors assays
To assay for biofilm formation of P. aeruginosa an over-
night culture was used to inoculate (~10
6 cells/ml) pep-
tone soy broth media in 96 wells plates (Falcon 353072)
in the presence or absence of recombinant peptide. The
peptides were resuspended in 10 mM phosphate buffer
(pH 7.4). The plate was incubated at 30°C for 26 h with-
out agitation. The amounts of biofilm were determined
by the method described by Peeters et al. [66] using the
dye crystal violet. Alginate production of P. aeruginosa
from a 24 h culture was assayed according to the proce-
dure described by Pedersen et al. [67]. The enzymatic
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Page 11 of 13assay for lasB, from the cleared supernatants of a 24 h P.
aeruginosa culture, was performed with the Congo red
method as described previously [27]. The amounts of
pyoverdine secreted by the bacteria were estimated by
measuring the absorbance at 405 nm of the cleared cul-
ture supernatants from 24 h cultures of P. aeruginosa as
described by Ambrosi et al. [68].
Additional material
Additional file 1: Supplementary_Figures. Fig. S1 - Spin relaxation
data (R1,R 2 and NOE) and associated reduced spectral density mapping
values. Fig. S2 - Diffusion behavior of cementoin, H2O and bicelles in
different conditions.
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